574 related articles for article (PubMed ID: 32679922)
61. Advances of ultrasound in tumor immunotherapy.
Lin J; Wu Y; Liu G; Cui R; Xu Y
Int Immunopharmacol; 2024 Jun; 134():112233. PubMed ID: 38735256
[TBL] [Abstract][Full Text] [Related]
62. Noninvasive imaging in cancer immunotherapy: The way to precision medicine.
Du Y; Qi Y; Jin Z; Tian J
Cancer Lett; 2019 Dec; 466():13-22. PubMed ID: 31499119
[TBL] [Abstract][Full Text] [Related]
63. Cancer immunotherapy: an evolving paradigm.
Lin A
J Zhejiang Univ Sci B; 2022 Oct; 23(10):791-792. PubMed ID: 36226534
[TBL] [Abstract][Full Text] [Related]
64. Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.
Yuan J; Khilnani A; Brody J; Andtbacka RHI; Hu-Lieskovan S; Luke JJ; Diab A; Marabelle A; Snyder A; Cao ZA; Hodi FS
Eur J Cancer; 2021 Nov; 157():493-510. PubMed ID: 34561127
[TBL] [Abstract][Full Text] [Related]
65. Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy.
Luo W; Zheng L; Zhang T
Int Immunopharmacol; 2021 Jan; 90():107199. PubMed ID: 33246828
[TBL] [Abstract][Full Text] [Related]
66. Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
Carlson RD; Flickinger JC; Snook AE
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32283684
[TBL] [Abstract][Full Text] [Related]
67. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.
Lohmueller J; Finn OJ
Pharmacol Ther; 2017 Oct; 178():31-47. PubMed ID: 28322974
[TBL] [Abstract][Full Text] [Related]
68. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
Ott PA; Dotti G; Yee C; Goff SL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
[TBL] [Abstract][Full Text] [Related]
69. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
70. Novel immunotherapies in multiple myeloma.
Ohmine K; Uchibori R
Int J Hematol; 2022 Jun; 115(6):799-810. PubMed ID: 35583724
[TBL] [Abstract][Full Text] [Related]
71. A novel era of cancer/testis antigen in cancer immunotherapy.
Meng X; Sun X; Liu Z; He Y
Int Immunopharmacol; 2021 Sep; 98():107889. PubMed ID: 34174699
[TBL] [Abstract][Full Text] [Related]
72. Development of Cancer Immunotherapies.
DeLucia DC; Lee JK
Cancer Treat Res; 2022; 183():1-48. PubMed ID: 35551655
[TBL] [Abstract][Full Text] [Related]
73. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
[TBL] [Abstract][Full Text] [Related]
74. Cancer immunotherapy: it's time to better predict patients' response.
Pilard C; Ancion M; Delvenne P; Jerusalem G; Hubert P; Herfs M
Br J Cancer; 2021 Sep; 125(7):927-938. PubMed ID: 34112949
[TBL] [Abstract][Full Text] [Related]
75. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.
Hughes PE; Caenepeel S; Wu LC
Trends Immunol; 2016 Jul; 37(7):462-476. PubMed ID: 27216414
[TBL] [Abstract][Full Text] [Related]
76. Intratumoral Immunotherapy: From Trial Design to Clinical Practice.
Champiat S; Tselikas L; Farhane S; Raoult T; Texier M; Lanoy E; Massard C; Robert C; Ammari S; De Baère T; Marabelle A
Clin Cancer Res; 2021 Feb; 27(3):665-679. PubMed ID: 32943460
[TBL] [Abstract][Full Text] [Related]
77. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
Leko V; Rosenberg SA
Cancer Cell; 2020 Oct; 38(4):454-472. PubMed ID: 32822573
[TBL] [Abstract][Full Text] [Related]
78. Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer.
Kerr MD; McBride DA; Chumber AK; Shah NJ
Expert Opin Drug Discov; 2021 Jan; 16(1):89-99. PubMed ID: 32867561
[TBL] [Abstract][Full Text] [Related]
79. Targeting iNOS to increase efficacy of immunotherapies.
Ekmekcioglu S; Grimm EA; Roszik J
Hum Vaccin Immunother; 2017 May; 13(5):1105-1108. PubMed ID: 28121247
[TBL] [Abstract][Full Text] [Related]
80. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.
Zhang Y; Zhang Z
Cell Mol Immunol; 2020 Aug; 17(8):807-821. PubMed ID: 32612154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
